

# Improvement of Bovine Parainfluenza 3 Virus Production Yields and Capacities Using the Corning® HYPERFlask® Cell Culture Vessel

CORNING

## Application Note

François Côte, M.Sc.<sup>1</sup>, Sandrine Henin<sup>1</sup>, and Constanza Curotto<sup>2</sup>

<sup>1</sup>Immunobiology Lab, CER Groupe, Aye, Belgium

<sup>2</sup>Corning Incorporated, Life Sciences, Amsterdam

## Introduction

Parainfluenza 3 (PI3V) is a major virus that causes respiratory diseases, ranging from common cold to advanced pneumonia, in calves. This results in a high susceptibility to secondary infections that could be potentially fatal for the infected animals. Virus transmission occurs through respiratory aerosols or direct contact with infected animals, which results in a highly contagious disease that needs to be carefully monitored to reduce incidence and enable disease control.

Diagnostic kits are widely available to control the serological status of cattle related to PI3V. In these kits, viruses of interest are captured by exposing specific monoclonal antibodies to bovine serum. Specific antibodies from seropositive animals bind viruses, which then are detected with a horseradish peroxidase (HRP)-conjugated anti-bovine immunoglobulin antibody. Reproducible batches of PI3V are required to manufacture these kits. Virus productions are performed through *in vitro* methods in which Madin-Darby Bovine Kidney (MDBK) cells are grown and infected with a small quantity of virus from a standard bank to produce a highly concentrated batch. In view of the virus quantities required to produce these kits, the production is generally performed using multiple layer culture vessels such as the competitor vessel.

However, in large scale production, the manipulation of bulky stacked vessels can be labor-intensive, which not only increases the chance of contamination during the production process but also requires a significant amount of incubator space. With its revolutionary design, the Corning HYPERFlask vessel provides ten compact interconnected layers of growth surfaces. This vessel utilizes a gas-permeable film to provide oxygen and carbon dioxide exchange, resulting in gas exposure to a large surface area within the flask. By eliminating the headspace, the HYPERFlask vessel provides a total area of 1,720 cm<sup>2</sup>, which is equivalent to ten T-175 flasks within the same footprint of one T-175, greatly increasing the viral production for a given amount of incubator footprint.

In an attempt to simplify the production of viral diagnostic reagents, we determined the suitability of the HYPERFlask cell culture vessels by comparing production yields and practical considerations against a competitor vessel, the traditional production vessel for this process. Conclusions were greatly in favor of the use of the HYPERFlask in terms of production yields, capacities, and practical aspects.

## Materials and Methods

### Cell Culture

Madin-Darby Canine Kidney (MDBK) cells were grown and maintained in 1X Dulbecco's Modified Eagle Medium (DMEM) containing 2 mM L-Glutamine (Lonza Cat. No. BE17-605E), 0.075% Sodium Bicarbonate (Thermo Fisher Cat. No. 25080-094), 50 µM 2-mercaptoethanol (Thermo Fisher Cat. No. 31350-010), 100U/100 µg Penicillin and Streptomycin (Lonza Cat. DE17-602E), and 10% heat-inactivated fetal bovine serum (FBS, GE Healthcare Cat. No. SV30160.03), and incubated at 37°C, 5% CO<sub>2</sub>.

### Viruses

The virus used in this study was the Loverix PI3V strain. Virus stocks were previously produced according to CER Groupe SOP, i.e. by preparing master and working viral banks that were both stored at -80°C and characterized by viral titration and immunolabelling with specific antibodies.

### Virus Production

The day before virus inoculation, all cells from two T-175 flasks were seeded into one HYPERFlask vessel (Corning Cat. No. 10024) and incubated at 37°C, 5% CO<sub>2</sub>. The same operation was performed with a competitor vessel, starting from six T-175 flasks to achieve the same cell number/surface ratio as in the HYPERFlask vessel, which has approximately one-third the total surface area as the competitor vessel. The next day, 1.2 x 10<sup>6</sup> TCID<sub>50</sub>/cm<sup>2</sup> of PI3V working virus bank was inoculated into the HYPERFlask and the competitor vessel. Following an incubation period of 3 days, supernatants were harvested, aliquoted and frozen at -70°C.

### Virus Titration

In order to quantify the viral productions, one cryogenic vial of each virus supernatant was used to perform the virus titration by immunolabeling. Briefly, MDBK cells were seeded in 96-well microplates, and serial dilutions of the viral productions were added to the wells, two microplates by virus sample. Following an incubation period of 4 days in an incubator at 37°C and 5% CO<sub>2</sub>, wells were fixed with a solution of PBS-formol, rinsed with PBS, incubated with anti-PI3V monoclonal antibodies conjugated to HRPO (CER Groupe Cat. No. I7D4G6-HRP), washed with PBS, revealed with AEC substrate, washed with PBS, and analyzed under an inverted microscope. Viral titers were calculated based on the number of infected wells at the dilution of interest.

## Results

### Virus Growth in the Corning® HYPERFlask® Vessel

A compact cell culture flask with multiple layers provides a significant advantage for large scale virus production. Providing an easier manipulation and saving incubator space. Due to its innovative design, the HYPERFlask vessel was tested for the production of Parainfluenza 3 virus.


MDBK cells were grown in a 10-layer competitor vessel and the HYPERFlask vessel, after which the culture was infected with PI3V to proceed with the virus amplification. At the end of the production period, supernatants were collected and frozen to release viral particles remaining into host cells by disruption of cell membranes. The amount of virus produced after a 3-day incubation period was compared for each vessel.

We observed that both systems enabled viral infection. Results of subsequent virus titrations are summarized in Table 1 and represented in Figures 1 and 2. In Table 1, a column summarizing results obtained with the eight last batches of PI3V was also included in the analysis to give an overview of mean productivities.


Concerning PI3V production (Figure 1), we observed that titers were slightly higher in the competitor vessel compared to the HYPERFlask vessel. However, we noted that production levels observed in the HYPERFlask vessel were in the range of previous batches produced recently, with results slightly above mean log TCID<sub>50</sub>. In addition, it's important to highlight that only two HYPERFlask vessels were required to produce the same quantity of virus compared to the competitor 10-layer vessel. Which is a great advantage in view of the space required in an incubator to maintain a HYPERFlask vessel compared to the competitor vessel. So, bigger batches can be produced easily. Moreover, when we compared the quantity of virus produced by cm<sup>2</sup> (Figure 2), we observed that this parameter was twice the value in the HYPERFlask vessel as in the competitor vessel.

The higher productivity observed in the HYPERFlask vessel may be related to the improved metabolism conditions within the culture, achieved by the improved design of this vessel. The proprietary design of the HYPERFlask vessel enables a better gas exchange in comparison to a traditional stacked vessel, where the gas exchange occurs via the vented cap and headspace. In terms of the manufacturing process, it's also possible to manage several HYPERFlask vessels in parallel in an incubator, resulting in a clear advantage of the HYPERFlask vessel for viral production. It is also worth noting that no preliminary optimization was performed to reach these production levels.

Finally, we can also mention that the HYPERFlask vessel was also preferred by our technicians from a practical point of view, in the sense that these vessels were easier to manipulate, to place under the laminar flow hood, to perform medium exchange, and to maintain compared to the competitor vessel.



**Figure 1.** Virus Production per mL of PI3V in the Corning HYPERFlask vessel and competitor vessel.



**Figure 2.** Productivity per cm<sup>2</sup> of PI3V in Corning HYPERFlask vessel and competitor vessel.

**Table 1.** Production Results of PI3V in Corning HYPERFlask and competitor vessel.

Target Virus	PI3V		
	Corning HYPERFlask Cell Culture Vessel	Competitor Vessel	Previous Batches (Competitor Vessel) Mean Value
Titer (log TCID <sub>50</sub> /mL)	8.60	8.80	8.35 (SD = 0.78)
Volume (mL)	560	675*	675
Total production (log TCID <sub>50</sub> )	11.35	11.63	11.17
Surface (cm <sup>2</sup> )	1720	6320	6320
Productivity (TCID <sub>50</sub> /cm <sup>2</sup> )	1.30 x 10 <sup>8</sup>	6.74 x 10 <sup>7</sup>	2.39 x 10 <sup>7</sup>

\*This reflects a modified protocol routinely used in virus production.

## Conclusions

- ▶ The Corning® HYPERFlask® vessel was demonstrated to be an effective method of producing PI3V for diagnostic kits.
- ▶ This method requires fewer flasks to produce the same amount of virus with less manipulation, resulting in significant time savings and reduction of contamination risk.
- ▶ The small footprint of this vessel also allows for a large amount of virus to be produced in a limited incubator space.
- ▶ In addition, the HYPERFlask vessel achieved higher productivity than the competitor vessel in terms of yield per cm<sup>2</sup>, thus constituting an economic solution for PI3V production.

For more specific information on claims, visit the Certificates page at [www.corning.com/lifesciences](http://www.corning.com/lifesciences).

**Warranty/Disclaimer:** Unless otherwise specified, all products are for research use only. Not intended for use in diagnostic or therapeutic procedures. Not for use in humans. Corning Life Sciences makes no claims regarding the performance of these products for clinical or diagnostic applications.

# CORNING

## Corning Incorporated Life Sciences

836 North St.  
Building 300, Suite 3401  
Tewksbury, MA 01876  
t 800.492.1110  
t 978.442.2200  
f 978.442.2476

[www.corning.com/lifesciences](http://www.corning.com/lifesciences)

### ASIA/PACIFIC

**Australia/New Zealand**  
t 61 427286832

**Chinese Mainland**  
t 86 21 3338 4338  
f 86 21 3338 4300

**India**  
t 91 124 4604000  
f 91 124 4604099

### Japan

t 81 3-3586 1996  
f 81 3-3586 1291

### Korea

t 82 2-796-9500  
f 82 2-796-9300

### Singapore

t 65 6572-9740  
f 65 6735-2913

### Taiwan

t 886 2-2716-0338  
f 886 2-2516-7500

### EUROPE

CSEurope@corning.com

### France

t 0800 916 882  
f 0800 918 636

### Germany

t 0800 101 1153  
f 0800 101 2427

### The Netherlands

t 020 655 79 28  
f 020 659 76 73

### United Kingdom

t 0800 376 8660  
f 0800 279 1117

### All Other European Countries

t +31 (0) 206 59 60 51  
f +31 (0) 206 59 76 73

### LATIN AMERICA

grupoLA@corning.com

### Brazil

t 55 (11) 3089-7400

### Mexico

t (52-81) 8158-8400

For additional product or technical information, visit [www.corning.com/lifesciences](http://www.corning.com/lifesciences) or call 800.492.1110. Outside the United States, call +1.978.442.2200 or contact your local Corning sales office.